MS
RAPP

Maven Securities’s Rapport Therapeutics RAPP Stock Holding History

Maven Securities’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$594K – 574
2025
Q3 		$594K Buy
+20,000
New +$357K 0.01% 402
2024
Q4 		– Sell
-29,930
Closed -$613K – 1049
2024
Q3 		$613K Buy
+29,930
New +$643K 0.01% 611

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Maven Securities's RAPP Position: Q4 2025 in Review

Maven Securities sold out of Rapport Therapeutics (RAPP) in Q4 2025, closing a stake of 20,000 shares — an estimated $594K sold.

Maven Securities first reported a position in RAPP in Q3 2024 and held it in 2 quarters. The position peaked at $613K in Q3 2024. 144 funds tracked by Wall St. Rank hold RAPP as of Q4 2025.

  • Maven Securities reported no remaining Rapport Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Maven Securities sold 20,000 Rapport Therapeutics shares in Q4 2025, an estimated $594K.
  • Maven Securities first reported a position in Rapport Therapeutics in Q3 2024 and held it in 2 quarters.
  • Maven Securities's Rapport Therapeutics position peaked at $613K in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q4 2025.

Based on Maven Securities's 13F filing for Q4 2025, filed 13 Feb 2026.